ahc 52 has been researched along with Leukemia P388 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ebisu, H; Inaba, M; Mitsuhashi, J; Shinoda, H; Tsuruo, T | 1 |
| Inaba, M; Shinoda, H; Tsuruo, T | 1 |
2 other study(ies) available for ahc 52 and Leukemia P388
| Article | Year |
|---|---|
Therapeutic efficacy of combination of antitumor agent with AHC-52 against multidrug-resistant cells in the intravenously inoculated P388 leukemia model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dihydropyridines; Doxorubicin; Drug Resistance; Drug Synergism; Etoposide; Female; Leukemia P388; Mice; Mice, Inbred BALB C; Mice, Inbred DBA; Pyrazoles; Vincristine | 1992 |
In vivo circumvention of vincristine resistance in mice with P388 leukemia using a novel compound, AHC-52.
Topics: Animals; Dihydropyridines; Drug Resistance; Drug Synergism; Female; Leukemia P388; Leukemia, Experimental; Mice; Mice, Inbred BALB C; Mice, Inbred DBA; Nifedipine; Pyrazoles; Vincristine | 1989 |